Federico Perez1, Maria Virginia Villegas. 1. aLouis Stokes Cleveland Department of Veterans Affairs Medical Center and Case Western Reserve University School of Medicine, Cleveland, Ohio, USA bCentro Internacional de Entrenamiento e Investigaciones Medicas, Cali, Colombia.
Abstract
PURPOSE OF REVIEW: It is widely accepted that infection control, advanced diagnostics, and novel therapeutics are crucial to mitigate the impact of antibiotic-resistant bacteria. The role of global, national, and regional surveillance systems as part of the response to the challenge posed by antibiotic resistance is not sufficiently highlighted. We provide an overview of contemporary surveillance programs, with emphasis on gram-negative bacteria. RECENT FINDINGS: The WHO and public health agencies in Europe and the United States recently published comprehensive surveillance reports. These highlight the emergence and dissemination of carbapenem-resistant Enterobacteriaceae and other multidrug-resistant gram-negative bacteria. In Israel, public health action to control carbapenem-resistant Enterobacteriaceae, especially Klebsiella pneumoniae carbapenemase producing K. pneumoniae, has advanced together with a better understanding of its epidemiology. Surveillance models adapted to the requirements and capacities of each country are in development. SUMMARY: Robust surveillance systems are essential to combat antibiotic resistance, and need to emphasize a 'one health' approach. Refinements in surveillance will come from advances in bioinformatics and genomics that permit the integration of global and local information about antibiotic consumption in humans and animals, molecular mechanisms of resistance, and bacterial genotyping.
PURPOSE OF REVIEW: It is widely accepted that infection control, advanced diagnostics, and novel therapeutics are crucial to mitigate the impact of antibiotic-resistant bacteria. The role of global, national, and regional surveillance systems as part of the response to the challenge posed by antibiotic resistance is not sufficiently highlighted. We provide an overview of contemporary surveillance programs, with emphasis on gram-negative bacteria. RECENT FINDINGS: The WHO and public health agencies in Europe and the United States recently published comprehensive surveillance reports. These highlight the emergence and dissemination of carbapenem-resistant Enterobacteriaceae and other multidrug-resistant gram-negative bacteria. In Israel, public health action to control carbapenem-resistant Enterobacteriaceae, especially Klebsiella pneumoniae carbapenemase producing K. pneumoniae, has advanced together with a better understanding of its epidemiology. Surveillance models adapted to the requirements and capacities of each country are in development. SUMMARY: Robust surveillance systems are essential to combat antibiotic resistance, and need to emphasize a 'one health' approach. Refinements in surveillance will come from advances in bioinformatics and genomics that permit the integration of global and local information about antibiotic consumption in humans and animals, molecular mechanisms of resistance, and bacterial genotyping.
Authors: James A Karlowsky; Laurie J Kelly; Clyde Thornsberry; Mark E Jones; Alan T Evangelista; Ian A Critchley; Daniel F Sahm Journal: Int J Antimicrob Agents Date: 2002-01 Impact factor: 5.283
Authors: Dawn M Sievert; Philip Ricks; Jonathan R Edwards; Amy Schneider; Jean Patel; Arjun Srinivasan; Alex Kallen; Brandi Limbago; Scott Fridkin Journal: Infect Control Hosp Epidemiol Date: 2012-11-27 Impact factor: 3.254
Authors: M Cuenca-Estrella; C B Moore; F Barchiesi; J Bille; E Chryssanthou; D W Denning; J P Donnelly; F Dromer; B Dupont; J H Rex; M D Richardson; B Sancak; P E Verweij; J L Rodríguez-Tudela Journal: Clin Microbiol Infect Date: 2003-06 Impact factor: 8.067
Authors: Evan S Snitkin; Adrian M Zelazny; Pamela J Thomas; Frida Stock; David K Henderson; Tara N Palmore; Julia A Segre Journal: Sci Transl Med Date: 2012-08-22 Impact factor: 17.956
Authors: Gaelle Cuzon; Thierry Naas; HaVy Truong; Maria Virginia Villegas; Karin T Wisell; Yehuda Carmeli; Ana C Gales; Shiri Navon Venezia; John P Quinn; Patrice Nordmann Journal: Emerg Infect Dis Date: 2010-09 Impact factor: 6.883
Authors: Douglas Teodoro; Emilie Pasche; Julien Gobeill; Stéphane Emonet; Patrick Ruch; Christian Lovis Journal: J Med Internet Res Date: 2012-05-29 Impact factor: 5.428
Authors: Michael A Pfaller; Michael D Huband; Dee Shortridge; Robert K Flamm Journal: Antimicrob Agents Chemother Date: 2020-04-21 Impact factor: 5.191
Authors: Michael A Pfaller; Michael D Huband; Paul R Rhomberg; Robert K Flamm Journal: Antimicrob Agents Chemother Date: 2017-04-24 Impact factor: 5.191
Authors: Heather I Henderson; Sonia Napravnik; Emily W Gower; Allison E Aiello; Alan C Kinlaw; Billy Williams; David A Wohl; David van Duin Journal: Clin Infect Dis Date: 2022-08-24 Impact factor: 20.999
Authors: Timothy J Johnson; Meggan E Craft; Katherine E L Worsley-Tonks; Stanley D Gehrt; Elizabeth A Miller; Randall S Singer; Jeff B Bender; James D Forester; Shane C McKenzie; Dominic A Travis Journal: Appl Environ Microbiol Date: 2021-07-13 Impact factor: 4.792
Authors: Anthony K Mbonye; Esther Buregyeya; Elizeus Rutebemberwa; Siân E Clarke; Sham Lal; Kristian S Hansen; Pascal Magnussen; Philip LaRussa Journal: BMJ Open Date: 2016-03-15 Impact factor: 2.692